---
title: "Xinbang Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 41.2442 million yuan, a decrease of 29.89%"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/238032668.md"
description: "Xinbang Pharmaceutical released its Q1 2025 performance, with operating revenue of 1.441 billion yuan, a year-on-year decrease of 8.93%; net profit attributable to the parent company of 41.2442 million yuan, a year-on-year decline of 29.89%; net profit excluding non-recurring gains and losses of 41.0754 million yuan, a year-on-year decrease of 30.16%; basic earnings per share of 0.02 yuan"
datetime: "2025-04-29T10:33:09.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/238032668.md)
  - [en](https://longbridge.com/en/news/238032668.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/238032668.md)
---

> Supported Languages: [简体中文](https://longbridge.com/zh-CN/news/238032668.md) | [繁體中文](https://longbridge.com/zh-HK/news/238032668.md)


# Xinbang Pharmaceutical released its first-quarter performance, with a net profit attributable to the parent company of 41.2442 million yuan, a decrease of 29.89%

According to the Zhitong Finance APP, Xinbang Pharmaceutical (002390.SZ) released its first-quarter report for 2025, showing an operating income of 1.441 billion yuan, a year-on-year decrease of 8.93%. The net profit attributable to shareholders of the listed company was 41.2442 million yuan, a year-on-year decrease of 29.89%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 41.0754 million yuan, a year-on-year decrease of 30.16%. The basic earnings per share were 0.02 yuan

### Related Stocks

- [xinbang phar. (002390.CN)](https://longbridge.com/en/quote/002390.CN.md)